An interventional study of mobile venous thromboembolism application (mVTEA) in Venous Thromboembolism, Digital Health and Health Education, sponsored by Navy General Hospital, Beijing. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Navy General Hospital, Beijing · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Venous Thromboembolism with a site in China — 21 open to participants now, 23 under way, 2 of them phase 3. Venous Thromboembolism · China.
Among the 62 studies in Venous Thromboembolism with a site in China, this one is the 26th largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2024, is one of 10 with no phase, reaches primary completion later than 7 of the 22 other live ones, and was the 46th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →21 of the 62 studies in Venous Thromboembolism with a site in China are open now. Recruiting first, the newest first:
Navy General Hospital, Beijing · Sites in China
Ages 18+
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
China-Japan Friendship Hospital · Sites in China
Ages 14+
The First Hospital of Jilin University · Sites in China
Ages 18+
Chen Lijuan · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is close to the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 530 across the 33 interventional studies, 1,174 across the 29 observational. Of the 31 that completed or were terminated, 5 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 62 have an industry lead sponsor. The 10 most frequent:
Navy General Hospital, Beijing is the lead sponsor of 36 studies on the registry; 22 are open to participants now.
Navy General Hospital, Beijing has 4 studies filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
6 of the studies in Venous Thromboembolism with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06580223Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | 2027-09-01 |
| NCT02832245Manuel MonrealComputerized Registry of Patients With Venous Thromboembolism (RIETE) | 2026-12 |
| NCT07907211Chen LijuanAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | 2026-12-31 |
| NCT06950697Beijing Chao Yang HospitalDevelopment and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors | 2026-12-31 |
| NCT05378308Henan Provincial People's HospitalNOACs Use in AF or VTE (SUNSHINE Registry) | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 62 studies in Venous Thromboembolism with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on patients' perceptions of thromboprophylaxis, in order to enhance clinical practice and establish a foundation of evidence for managing patients with VTE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomly assigned to the mVTEA management group will be discharged with mVTEA-assisted patient-centered VTE management.
Other: mobile venous thromboembolism application (mVTEA)
Patients randomly assigned to the routine management group will be given routine post-discharge management in accordance with local clinical practice.
mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.
VTE-KAP questionnaire score
The VTE-KAP questionnaire is a self-administered questionnaire that includes demographic characteristics, knowledge, attitude, and practice (KAP) of patients towards VTE prevention and treatment. The VTE-KAP questionnaire consists of a total of 53 questions with an overall score range of 41 to 283. The higher the score, the higher the level of knowledge, attitude, and practice. The VTE-KAP questionnaire scores will be evaluated at the third-month follow-up after discharge.
Time frame: The third month after discharge from the hospital
Knowledge, attitude, and practice scores in the VTE-KAP questionnaire
The knowledge domain contains 7 questions to assess patients' levels of knowledge regarding VTE prevention and treatment. The total score of knowledge for each study participant ranged from 7 to 53. The attitude domain contains 20 questions to assess patients' attitudes towards VTE prevention and treatment. Each question was scored and the final attitude score ranged between 20 and 100. The practice domain contained 26 questions with a score range of 21 to 130 for assessing the implementation of VTE prevention and treatment behaviors in the study patients. The higher the score, the higher the level of knowledge, attitude and practice. The patients' knowledge, attitude, and practice scores in the VTE-KAP questionnaire will be assessed at the third-month follow-up after discharge separately.
Time frame: The third month after discharge from the hospital
Generic quality of life
Generic, non-disease-specific health-related quality of life (QoL) is assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire and its corresponding visual analogue scale at the third-month follow-up after discharge. Briefly, the EQ-5D-5L generates an overall index that ranges from 0 (lowest generic QoL) to 1 (highest generic QoL) and is calculated based on country-specific reference value sets. The EQ-5D-5L health index was calculated with the value set for China. The EuroQol visual analogue scale ranges from 0 to 100, with higher scores indicating better health.
Time frame: The third month after discharge from the hospital
VTE events
VTE events will be documented during the 3-month follow-up after discharge. VTE events are categorized into three groups: new-onset VTE, hospital-acquired VTE (HA-VTE), and recurrent VTE. VTE that occurred for the first time during the study period, including deep vein thrombosis (DVT) and pulmonary embolism (PE), is classified as new-onset VTE. HA-VTE is defined as any new-onset VTE that has occurred within 90 days of hospital discharge. Recurrent VTE is defined as the appearance of new evidence of VTE after acute VTE has been treated in the acute phase (2 weeks) with significant clinical improvement in signs and symptoms. According to the time of VTE recurrence, it is further categorized into early VTE recurrence (within 3 months after the last VTE occurrence) and late VTE recurrence (more than 3 months after the last VTE occurrence).
Time frame: 3 months after discharge
Chronic thromboembolic pulmonary hypertension (CTEPH)
The diagnosis of CTEPH will be documented at the third-month follow-up after discharge.
Time frame: The third month after discharge
Chronic thromboembolic pulmonary disease (CTEPD)
The diagnosis of CTEPD will be documented at the third-month follow-up after discharge.
Time frame: The third month after discharge
Post-pulmonary embolism syndrome (PPES)
The diagnosis of PPES will be documented at the third-month follow-up after discharge.
Time frame: The third month after discharge
Major bleeding
The major bleeding events as defined by the International Society on Thrombosis and Hemostasis (ISTH) will be documented during the 3-month follow-up after discharge.
Time frame: 3 months after discharge
VTE-related hospitalization
Hospitalization due to the new-onset DVT and/or PE will be documented during the 3-month follow-up after discharge.
Time frame: 3 months after discharge
VTE-related rehospitalization
Rehospitalization due to VTE recurrence, progression, or complications related to VTE treatment will be documented during the 3-month follow-up after discharge.
Time frame: 3 months after discharge
New-onset of atrial fibrillation or atrial flutter
The new-onset of atrial fibrillation or atrial flutter will be documented during the 3-month follow-up after discharge.
Time frame: 3 months after discharge
Death
Death will be documented during the 3-month follow-up after discharge. It is categorized into all-cause death and PE-related death. All-cause death is defined as death that occurs during the study period, regardless of cause.PE-related death is defined as death that is unequivocally due to PE.
Time frame: 3 months after discharge
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Sep 2025, 13 months after the start.
Of 65 non-industry interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 13 months is below that.
Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 19 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Navy General Hospital, Beijing